PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Profitability
This table compares PTC Therapeutics and Spyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | -3.80% | N/A | -1.32% |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
Risk and Volatility
PTC Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for PTC Therapeutics and Spyre Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 2 | 3 | 10 | 1 | 2.62 |
| Spyre Therapeutics | 1 | 1 | 13 | 2 | 2.94 |
PTC Therapeutics currently has a consensus target price of $94.93, indicating a potential upside of 50.87%. Spyre Therapeutics has a consensus target price of $110.40, indicating a potential upside of 20.79%. Given PTC Therapeutics’ higher possible upside, equities analysts plainly believe PTC Therapeutics is more favorable than Spyre Therapeutics.
Earnings and Valuation
This table compares PTC Therapeutics and Spyre Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $1.73 billion | 3.03 | $682.64 million | ($0.58) | -108.48 |
| Spyre Therapeutics | $890,000.00 | 10,465.81 | -$155.20 million | ($1.95) | -46.87 |
PTC Therapeutics has higher revenue and earnings than Spyre Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
80.4% of Spyre Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Spyre Therapeutics beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
